Filing Analysis
IO Biotech, Inc. has filed for voluntary Chapter 7 bankruptcy protection, ceased all operations, and terminated all employees and officers. The company expects that common stockholders will receive no distribution and has announced it will no longer file periodic reports with the SEC.
š© Red Flags
- Chapter 7 bankruptcy filing (liquidation rather than reorganization).
- Cessation of all business operations.
- Default on ā¬22.5 million in debt to the European Investment Bank.
- Total resignation of the Board of Directors and termination of all staff.
- Explicit warning that common stock is likely worthless.
- Cessation of SEC reporting obligations.
š Key Facts
- Filed a voluntary petition for relief under Chapter 7 of the Bankruptcy Code on March 31, 2026, in the District of Delaware.
- The filing triggers an event of default on a finance contract with the European Investment Bank (EIB) for ā¬22.5 million.
- All six members of the Board of Directors resigned effective March 31, 2026.
- All employees and officers, including CEO Mai-Britt Zocca and CFO Amy Sullivan, were terminated without cause.
- The company will not complete its 2025 audit or file its Form 10-K for the fiscal year ended December 31, 2025.
IO Biotech, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum market value requirement for The Nasdaq Global Select Market. The company has 180 days to regain compliance by meeting the $50 million market value threshold.
š© Red Flags
- Delisting notice from Nasdaq
- Failure to meet minimum market value requirements (MVLS < $50M)
- Risk of delisting if compliance is not met by August 11, 2026
š Key Facts
- Received notice on February 12, 2026, regarding non-compliance with Nasdaq Listing Rule 5450(b)(2)(A).
- The deficiency is due to the Market Value of Listed Securities (MVLS) falling below $50 million for 30 consecutive business days.
- The company has a compliance period until August 11, 2026.
- To regain compliance, MVLS must meet or exceed $50 million for at least ten consecutive business days during the compliance period.
IO Biotech is undergoing significant restructuring and workforce reductions as part of a strategic effort to reduce operating expenses while exploring strategic alternatives. This includes the departure of the Chief Medical Officer and the retention of Raymond James & Associates as an exclusive financial advisor.
š© Red Flags
- Significant workforce reduction and restructuring plan.
- Exploration of 'strategic alternatives' (often a precursor to sale, merger, or bankruptcy).
- Departure of a named executive officer (Chief Medical Officer) during restructuring.
- One-time cash expenditures related to termination costs.
š Key Facts
- Board approved a restructuring and workforce reduction plan on January 21, 2026.
- Expected one-time charges/expenditures: $2.4 million to $2.6 million, primarily for severance and healthcare continuation.
- Charges are expected to be incurred primarily in Q1 2026.
- Chief Medical Officer Qasim Ahmad, M.D., will depart effective February 15, 2026.
- Retained Raymond James & Associates, Inc. as exclusive financial advisor for exploring strategic alternatives.
IO Biotech, Inc. announced on January 21, 2026, that it is exploring strategic alternatives for the company. This typically indicates a search for a buyer, merger partner, or restructuring to address liquidity or operational challenges.
š© Red Flags
- Exploration of 'strategic alternatives' is often a precursor to sale, merger, or bankruptcy proceedings.
- High uncertainty regarding the future existence and structure of the company.
š Key Facts
- Company plans to explore 'strategic alternatives' as of January 21, 2026.
- The announcement was made via a press release (Exhibit 99.1).
- CEO Mai-Britt Zocca, Ph.D. signed the filing.
IO Biotech, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum bid price requirement after its stock closed below $1.00 for 30 consecutive trading days. The company has an initial 180-day period to regain compliance.
š© Red Flags
- Delisting notice (minimum bid price deficiency)
- Stock has been trading below $1.00 for at least 30 consecutive days, indicating significant downward momentum or lack of investor confidence.
- Risk of being downgraded from Nasdaq Global Select Market to Nasdaq Capital Market.
š Key Facts
- Received notice on December 17, 2025, from Nasdaq Listing Qualifications staff.
- Non-compliance due to closing bid price falling below $1.00 for 30 consecutive trading days (Nasdaq Rule 5450(a)(1)).
- Initial compliance period granted until June 16, 2026.
- To regain compliance, stock must close at or above $1.00 for at least 10 consecutive trading days before the deadline.
- Potential for a second 180-day compliance period if the company transfers from Nasdaq Global Select Market to Nasdaq Capital Market.
IO Biotech announced the resignation of its Senior Vice President and Chief Accounting Officer, Brian Burkavage, effective December 12, 2025. The company's CFO, Amy Sullivan, will assume the role of principal accounting officer upon his departure.
š© Red Flags
- None identified; resignation is stated to be non-dispute related.
š Key Facts
- Brian Burkavage is resigning as SVP and Chief Accounting Officer on November 17, 2025, effective December 12, 2025.
- The resignation is for a new opportunity and not due to any disagreement with the Company.
- Amy Sullivan (CFO) will be designated as the principal accounting officer starting December 12, 2025.
- No new compensatory arrangements were entered into for Ms. Sullivan regarding this additional responsibility.
IO Biotech, Inc. filed an 8-K to announce its participation in the Jefferies Global Healthcare Conference and the release of an updated corporate presentation (Investor Deck). This is a routine disclosure under Regulation FD.
š Key Facts
- Company will participate in the Jefferies Global Healthcare Conference starting November 18, 2025.
- The company has released an updated Investor Deck to be used during the conference and investor meetings.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
IO Biotech, Inc. filed an 8-K to announce its financial results and operational update for the fiscal quarter ended September 30, 2025.
š Key Facts
- The filing pertains to the fiscal quarter ended September 30, 2025.
- The company issued a press release (Exhibit 99.1) containing financial results and operational updates.
- The report was signed by CEO Mai-Britt Zocca on November 14, 2025.
IO Biotech is implementing a major restructuring plan involving a 50% global workforce reduction to conserve capital. This follows an FDA recommendation that the company not submit a Biologics License Application (BLA) based on IOB-013 clinical trial data, which narrowly missed statistical significance.
š© Red Flags
- Significant workforce reduction (50%) indicating severe capital constraints.
- Major clinical setback: FDA recommendation against BLA submission for the IOB-013 trial.
- Clinical data narrowly missed statistical significance, jeopardizing the primary product's path to market.
š Key Facts
- Board approved a restructuring and workforce reduction plan on September 25, 2025.
- The Plan involves a reduction of approximately 50% of the Company's global workforce.
- Expected one-time charges/cash expenditures: $1.0 million to $1.5 million (primarily severance, wages, and healthcare).
- Charges expected primarily in Q3 2025; payments completed by Q4 2025.
- FDA recommended against BLA submission for IOB-013 clinical trial data due to narrow miss on statistical significance.
- Company is seeking an efficient path to market via potential additional registrational studies and EU regulatory discussions.
IO Biotech, Inc. filed an 8-K to announce its financial results and operational update for the fiscal quarter ended June 30, 2025.
š Key Facts
- Report date: August 14, 2025
- Reporting period: Fiscal quarter ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and operational updates.
- Company is an emerging growth company.
IO Biotech reported topline Phase 3 results for Cylembio in combination with pembrolizumab, showing a trend toward improved progression-free survival (PFS) in advanced melanoma. The company also disclosed its current cash position and projected runway into Q1 2026.
š© Red Flags
- The primary endpoint for PFS failed to reach statistical significance based on the pre-specified threshold (p=0.056 vs pā¤0.045).
- Cash runway is limited, extending only into the first quarter of 2026.
š Key Facts
- Estimated cash and cash equivalents: ~$28.1 million as of June 30, 2025.
- Received ā¬12.5 million from the second tranche of a term loan facility with the European Investment Bank on July 4, 2025.
- Phase 3 IOB-013 trial showed median PFS of 19.4 months for Cylembio + pembrolizumab vs. 11.0 months for pembrolizumab alone.
- PFS hazard ratio (HR) was 0.77 [95% CI: 0.58-1.00; p=0.056], narrowly missing the predefined significance threshold of pā¤0.045.
- Post hoc analysis in patients without prior anti-PD-1 treatment showed a significant HR of 0.74 (p=0.037).
- Company plans to meet with the FDA to discuss BLA submission for advanced melanoma.
IO Biotech has satisfied conditions to draw down the second ā¬12.5 million tranche of its term loan facility with the European Investment Bank (EIB). As part of this transaction, the company issued a Tranche B warrant to EIB allowing for the purchase of up to 4,221,867.59 shares at a strike price of $1.3159 per share.
š© Red Flags
- Issuance of warrants to a lender (EIB) can lead to future dilution for existing shareholders.
š Key Facts
- The Company satisfied conditions to draw ā¬12.5 million in the second tranche (Tranche B) of a term loan facility.
- Issued Tranche B Warrant to EIB on June 24, 2025.
- Warrant allows purchase of up to 4,221,867.59 shares of Common Stock.
- Strike price for the warrant is $1.3159 per share.
- Expected drawdown of the Tranche B loan on or around July 4, 2025.
IO Biotech, Inc. entered into an addendum to the service agreement for its CEO, Mai-Britt Zocca, outlining severance entitlements in the event of a 'Qualifying Termination'. The filing details specific compensation triggers including base salary, pro-rated bonuses, and equity acceleration.
š© Red Flags
- The filing outlines significant severance liabilities triggered by 'good reason' terminations or Change in Control events.
š Key Facts
- Addendum dated June 19, 2025, between IO Biotech ApS (subsidiary) and CEO Mai-Britt Zocca.
- Severance includes 12 months of base salary in the event of termination without 'cause' or by CEO for 'good reason'.
- Includes pro-rated bonus for the year of termination and any unpaid prior-year bonuses.
- Accelerated vesting of equity awards scheduled to vest within 12 months following a Qualifying Termination.
- Change in Control trigger: Severance increases to 18 months, full annual bonus (no proration), and 100% accelerated vesting of all outstanding equity.
IO Biotech, Inc. held its 2025 Annual Meeting of Stockholders on June 5, 2025. The meeting resulted in the election of a new Class I Director and the ratification of the company's independent auditor.
š Key Facts
- Annual Meeting held on June 5, 2025.
- David Smith was elected to the Board as a Class I Director (term ending at the 2026 Annual Meeting).
- Stockholders ratified EY Godkendt Revisionspartnerselskab as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Proposal One received 40,444,898 votes 'For' and 3,010,542 withheld.
IO Biotech, Inc. has regained compliance with Nasdaq's minimum bid price requirement after its stock traded below $1.00 for a period of time. The company successfully met the 10-consecutive-business-day threshold required to resolve the non-compliance notice.
š© Red Flags
- Historical non-compliance with Nasdaq minimum bid price requirement (stock fell below $1.00).
š Key Facts
- Received notice on December 26, 2024, regarding non-compliance with Nasdaq Listing Rule 5450(a)(1) due to stock price falling below $1.00 for 30 consecutive trading days.
- On June 3, 2025, the company received written notification that it has regained compliance.
- Compliance was achieved by maintaining a closing bid price of $1.00 or greater for at least 10 consecutive business days.
IO Biotech, Inc. filed an 8-K to announce its financial results and operational update for the fiscal quarter ended March 31, 2025.
š Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Reporting period: Fiscal quarter ended March 31, 2025.
- Date of report: May 14, 2025.
- The company is an emerging growth company.
IO Biotech has satisfied conditions to draw down the first ā¬10.0 million tranche of a term loan facility from the European Investment Bank (EIB). In connection with this drawdown, the company issued warrants to EIB for up to 5,623,664.38 shares at a strike price of $0.8891 per share.
š© Red Flags
- Issuance of significant warrants (over 5.6 million shares) at a strike price of $0.8891 suggests potential future dilution for existing shareholders.
- The financing is structured through a subsidiary and involves debt, which is common in biotech but increases leverage.
š Key Facts
- The company's subsidiary (IO Biotech ApS) is drawing down 'Tranche A' of a ā¬57.5 million total potential financing facility from the European Investment Bank (EIB).
- The Tranche A drawdown amount is ā¬10.0 million.
- A warrant was issued to EIB on April 24, 2025, allowing for the purchase of up to 5,623,664.38 shares of common stock.
- The strike price for the Tranche A Warrant is $0.8891 per share.
- The drawdown of the loan is expected to occur on or around May 6, 2025.
IO Biotech, Inc. disclosed its preliminary cash and cash equivalents balance of approximately $60 million as of December 31, 2024. The company also issued a press release containing business updates regarding clinical trials.
š© Red Flags
- Preliminary financial data: The $60 million cash figure is subject to change and may differ materially once audits are complete.
- Uncertainty in cash runway: While $60M is disclosed, the lack of finalized 2024 financials prevents a definitive assessment of burn rate vs. liquidity.
š Key Facts
- Cash and cash equivalents as of Dec 31, 2024: ~$60 million (preliminary).
- Financial statements for FY2024 are not yet finalized or audited.
- The company issued a press release on March 4, 2025, regarding clinical trial updates and cash position.
IO Biotech, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum $1.00 bid price requirement after its stock closed below $1.00 for 30 consecutive trading days. The company has been granted an initial 180-day compliance period to regain compliance.
š© Red Flags
- Delisting notice (minimum bid price deficiency).
- Potential downgrade from Nasdaq Global Select Market to Nasdaq Capital Market.
- Risk of total delisting if compliance is not met by June 2025 or during the appeal process.
š Key Facts
- Received notice from Nasdaq on December 26, 2024, regarding non-compliance with Nasdaq Listing Rule 5450(a)(1).
- The deficiency is due to the closing bid price falling below $1.00 for 30 consecutive trading days.
- Initial compliance period expires on June 24, 2025.
- To regain compliance, the stock must meet or exceed $1.00 per share for at least 10 consecutive trading days before the deadline.
- The company may be eligible for a second 180-day compliance period if it transfers from Nasdaq Global Select Market to Nasdaq Capital Market.
IO Biotech, Inc. entered into a multi-tranche loan facility with the European Investment Bank (EIB) totaling up to ā¬37.5 million to fund ongoing clinical trials. The agreement includes significant warrant issuances and registration rights for EIB, effectively creating potential future equity dilution.
š© Red Flags
- Significant potential dilution via warrant issuances and EIB's put option.
- Tranche C funding is contingent upon raising an additional $50 million in cash, indicating a high dependency on future capital markets access.
- The loan includes various acceleration events (Change of Control, Investment Cost Reduction) that could trigger immediate repayment obligations.
š Key Facts
- Total aggregate principal amount of the EIB Loan Facility is up to ā¬37.5 million across three tranches (A, B, and C).
- Tranche A (ā¬10.0M) and Tranche B (ā¬12.5M) are expected to be available in January 2025; Tranche C (ā¬15.0M) is subject to a $50M cash raise and regulatory milestones.
- All tranches bear a fixed annual interest rate of 8% with a six-year maturity from disbursement.
- The company issued warrants to EIB in connection with each tranche; the number of shares decreases as the stock price increases.
- EIB holds a put option to sell the Warrants back to the Company at fair market value or a strike price-adjusted amount upon maturity or specific events.
- Company is obligated to file registration statements for the warrants by May 15, 2025.
IO Biotech, Inc. announced that its Board of Directors adopted amended and restated bylaws effective December 13, 2024. The changes primarily involve procedural updates to stockholder nominations, director eligibility, and compliance with recent Delaware General Corporation Law amendments.
š Key Facts
- Board adopted Amended and Restated Bylaws on December 13, 2024.
- Amendments include revised mechanics for stockholder nominations of directors.
- Changes address Rule 14a-19 under the Exchange Act regarding proxy solicitations.
- Updates made to procedures relating to stockholder meetings.
- Bylaws updated to conform to recent amendments to Delaware General Corporation Law.
IO Biotech, Inc. filed an 8-K to furnish its quarterly earnings press release for the fiscal quarter ended September 30, 2024. The filing serves as a formal announcement of financial results and operational updates.
š Key Facts
- The company issued a press release on November 12, 2024, regarding financial results for the quarter ended September 30, 2024.
- The filing includes an update on the Company's operations for the same period.
- The information provided under Item 2.02 is furnished rather than filed, limiting liability under Section 18 of the Exchange Act.
IO Biotech announced that an Independent Data Monitoring Committee (IDMC) recommended the continuation of its pivotal Phase 3 trial for IO102-IO103 in combination with KEYTRUDA. The interim analysis showed no new safety signals and confirmed the trial should proceed without modifications.
š Key Facts
- Interim analysis conducted on the Phase 3 trial (IOB-013/KN-D18) for IO102-IO103 + KEYTRUDA in advanced melanoma.
- IDMC recommended continuation of the trial without modifications based on safety and efficacy data.
- No new safety signals were observed during the per-protocol interim analysis.
- The primary endpoint of progression-free survival (PFS) is projected to be reached in H1 2025.
IO Biotech, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2024, and provided an operational update via a press release.
š Key Facts
- The filing reports on the fiscal quarter ended June 30, 2024.
- The company issued a press release (Exhibit 99.1) containing financial results and operational updates.
- The report was signed by CEO Mai-Britt Zocca, Ph.D.
IO Biotech, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 6, 2024. The meeting involved the election of three Class III directors and the ratification of the company's independent auditor.
š Key Facts
- Annual Meeting held on June 6, 2024.
- Kathleen Sereda Glaub, Peter Hirth, and Mai-Britt Zocca were elected to serve as Class III directors until the 2027 Annual Meeting.
- Stockholders ratified the appointment of EY Godkendt Revisionspartnerselskab as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Proposal One (Director Election) received significant 'For' votes: Glaub (43.0M), Hirth (42.3M), and Zocca (43.2M).
IO Biotech, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2024 and provided an operational update.
š Key Facts
- Report date: May 14, 2024
- Reporting period: Fiscal quarter ended March 31, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results and operational updates.
- Company is an emerging growth company.
IO Biotech, Inc. announced the resignation of board member Jack Nielsen, effective April 24, 2024. The departure is attributed to health reasons and not due to any disagreement with the company.
š Key Facts
- Jack Nielsen resigned from the Board of Directors on April 24, 2024.
- The resignation was effective immediately upon notification.
- The company explicitly stated the departure is for health reasons and not due to disagreements regarding operations, policies, or practices.
IO Biotech, Inc. issued an 8-K to furnish its year-end financial results for the period ending December 31, 2023, and provided a general operational update via press release.
š Key Facts
- Report date: March 5, 2024
- Reporting period: Year ended December 31, 2023
- The filing is for the purpose of furnishing results of operations and financial condition (Item 2.02)
- Information provided in Exhibit 99.1 is furnished but not 'filed' under Section 18 of the Exchange Act.
IO Biotech, Inc. announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference and released an updated corporate presentation. The filing specifically highlights that the company's projected cash runway extends through the fourth quarter of 2025.
š© Red Flags
- Cash runway visibility (while positive for the immediate term, it highlights the inherent burn rate risk of biotech firms).
š Key Facts
- Company to participate in the 42nd Annual J.P. Morgan Healthcare Conference starting January 8, 2024.
- Updated Investor Deck released on January 8, 2024.
- Projected cash runway is confirmed through Q4 2025.